Clinical Trials Logo

Clinical Trial Summary

Robot-assisted surgery has been successfully adopted rapidly over the last decade. Robotic technology with tridimensional imaging can improve operating dexterity, visualization of difficult anatomic locations. This is a prospective study aims to evaluate the safety and effectiveness of the domestic surgical robot.


Clinical Trial Description

In this clinical trial, the subjects will be randomly divided into two groups, and the urological typical surgical procedures (prostatectomy, and partial or radical nephrectomy) will be performed with the endoscopic surgical instrument control system SP1000 and IS3000.And the non-inferiorly comparison will be made between the surgical results of two systems to verify the safety and effectiveness of the endoscopic surgical instrument control system (SP1000). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05025930
Study type Interventional
Source Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Contact Kaiwen Li, MD
Phone +86-02034078960
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date October 1, 2021
Completion date September 30, 2023

See also
  Status Clinical Trial Phase
Completed NCT00151034 - Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer Phase 2
Completed NCT04933604 - LPN in Patients With High-complex Renal Tumors
Active, not recruiting NCT03219333 - A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer Phase 2
Completed NCT04052113 - Real World Evidence of PD-L1, TMB Prevalence and Efficacy of 1st Line Chemotherapy in These High or Low Population for Stage IV Urothelial Cancer
Terminated NCT02543645 - A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer Phase 1
Completed NCT01454089 - A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer Phase 2
Recruiting NCT03288545 - A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer Phase 1/Phase 2
Recruiting NCT04630483 - Platelet-lymphocyte and Neutrophil-lymphocyte Ratio in Patients Undergoing Cancer Surgery
Terminated NCT02386111 - A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma Phase 1
Active, not recruiting NCT03081858 - Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer Phase 1/Phase 2
Recruiting NCT04644432 - Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma Phase 2
Terminated NCT00226954 - Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer Phase 2
Completed NCT04213157 - Laparoscopic Partial Nephrectomy for cT1 Tumors
Completed NCT02780687 - Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy Phase 2
Recruiting NCT04922047 - Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01) Phase 1/Phase 2
Active, not recruiting NCT03091192 - Savolitinib vs. Sunitinib in MET-driven PRCC. Phase 3
Recruiting NCT04442724 - Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy N/A
Active, not recruiting NCT03595813 - Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy N/A
Completed NCT02891460 - Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients N/A
Completed NCT00191971 - 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen Phase 2